NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis

Dedicated patient and caregiver support

For patients living with a serious health condition, and their caregivers, connection to others who understand their unique circumstances can be essential. This kind of support is at the heart of Acadia Connect.

Acadia Connect is a comprehensive support program for patients prescribed treatments from Acadia Pharmaceuticals that offers guidance on enrollment, patient access, insurance coverage, financial assistance, and prescription support.

We’re here to connect you and your patients to the right support every step of the way.

Acadia Connect

Acadia Connect enrollment

Enrollment is simple

If you need to get a prescription for your patient, fill out the Treatment Form, including the section for the free 14-day supply.* You may also download the PDF version of the form and fax it to 1-844-737-2223.

Start treatment form

*Appropriate patients must be enrolled in Acadia Connect to be eligible for the free 14-day supply. Acadia Connect patient eligibility and terms and conditions apply.

If you need long-term care access services, fill out the Long-Term Care Service Request Form. You may also download the PDF version of the form and fax it to 1-844-737-2223.

Start long-term care form

Your office will be paired with a local Patient Access Manager who offers in-office education and resources to help facilitate access to the medication you prescribe.

Your enrolled patients will be assigned a dedicated Care Coordinator they can turn to for insurance questions and financial resources.

Cost & coverage

Your patient’s prescription may be more affordable than you expect, thanks to comprehensive coverage and financial assistance options when enrolled in Acadia Connect.

  • 100% of Medicare Part D plans cover NUPLAZID1

  • 80% of patients pay less than $10 for their NUPLAZID prescription

  • $0 co-pay for qualifying commercially covered patients

See prescription 
coverage options

Around 20% of residents may pay more than $10 for their prescription. As reported by four specialty pharmacy organizations; Q1 2020 data.

Tools to assist you

These simple tools were created to help you enroll your patients in Acadia Connect and get them started on their prescription medication.

Formulary lookup

See if your patient’s insurance will cover NUPLAZID.

Use formulary tool

Prior authorization

Your patient may need authorization to get insurance coverage for NUPLAZID.

Start a request

Letter forms

Find templates in the event your patients need a letter of appeal or letter of medical necessity. You can also download PDF versions of the letter of appeal template and the letter of medical necessity template.

Create letters

Diagnostic codes - PD

Diagnostic codes for easy reference

Details on Parkinson's disease (PD) psychosis ICD-10 codes

Here’s a quick list of what you need to know about ICD-10 codes for patients with PD-related hallucinations and delusions.

For diagnostic codes in treating PD psychosis*: Coding must be to the highest level of specificity.

All coding decisions are ultimately the responsibility of each prescribing healthcare provider.

Coding combinations recognized for PD psychosis include G20 (PD) plus one of the following ICD-10 codes¹:

  • F06.0 Psychotic disorder with hallucinations due to known physiological condition

  • F06.2 Psychotic disorder with delusions due to known physiological condition

*Diagnostic codes are not required to complete the NUPLAZID treatment form.

Questions? Connect with an Acadia Connect representative.

1-844-737-2223
Monday through Friday
8:30 AM-8:30 PM ET

Visit the Acadia Connect website to learn how we can help you and your patients get started with NUPLAZID.

IMPORTANT SAFETY INFORMATION and INDICATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation

    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.

    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

  • Adverse Reactions: The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

  • Drug Interactions:

    • Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.

    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Indication NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.

Reference:
  1. Managed Markets Insight & Technology. Formulary Lookup website. https://formularylookup.com. Accessed August 4, 2020.